Totarol

Totarol

SCHEMBL285501

CC(C)c1c(O)ccc2c1CC[C@H]1C(C)(C)CCC[C@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 1.00
MAPT P10636 4/20 1.00
USP2 O75604 4/20 1.00
TP53 P04637 4/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
MAPK1 P28482 2/20 1.00
HSP90AA1 P07900 1/20 1.00
KDM4E B2RXH2 1/20 1.00
HPGD P15428 1/20 0.74
ALOX15 P16050 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.69
PIP5K1A Q99755 4/20 0.50
CYP19A1 P11511 1/20 0.50
CSNK2A2 P19784 2/20 0.48
CSNK2B P67870 2/20 0.48
CSNK2A1 P68400 2/20 0.48
CSNK2A3 Q8NEV1 2/20 0.48
CETP P11597 3/20 0.45
KARS1 Q15046 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Totarol SCHEMBL1839596 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL13423504 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL30105648 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL16238019 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL31121504 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
19-Hydroxytotarol SCHEMBL12998342 0.85 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
19-Hydroxytotarol SCHEMBL13423507 0.85 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL31287563 0.85 CYP3A4 (0.74) CYP3A4MAPTUSP2TP53MEN1
SCHEMBL5522477 0.84 CYP3A4 (0.78) CYP3A4MAPTUSP2TP53MEN1
SCHEMBL20970940 0.84 USP2 (0.82) CYP3A4MAPTUSP2TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260131121-A1 MICRONEEDLE PATCH DARWIN PRECISIONS CORP (TW) 2026-05-14 US claimed
EP-3436157-B1 METHOD AND COMPOSITION FOR TREATING SKIN CONDITIONS OREAL (FR) 2025-07-30 EP claimed
CN-118851849-A Organic chemical conversion method for exchange of hydrogen and deuterium containing electron-rich aromatic ring compound 河南工业大学 2024-10-29 CN claimed
CN-118680945-A Biofilm formation regulating composition containing persimmons and dipotassium glycyrrhizinate and application thereof 株式会社LG生活健康 2024-09-24 CN claimed
CN-115813822-B High-efficiency acne-removing composition and preparation method thereof 厦门海尼新创生物科技有限公司 2024-06-25 CN claimed
US-20240130979-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN CONDITIONS Epitop, Inc. 2024-04-25 US claimed
CN-116077423-B Female private care gel and preparation method and application thereof 阿基米德(广州)化妆品研究有限公司 2024-04-23 CN claimed
CN-117653561-A Anti-aging active composition, application thereof and anti-aging essential oil 长沙黛西生物科技有限公司 2024-03-08 CN claimed
EP-4326892-A1 METHOD FOR SELECTING ECOBIOLOGICAL TOPICAL COMPOSITIONS AND INGREDIENTS CAPABLE OF RESTORING OR REINFORCING THE SKIN MICROBIOTA NAOS Institute of Life Science (FR) 2024-02-28 EP claimed
CN-117257709-A Gum protecting and whitening tooth paste composition and preparation method thereof 广州丽润科技有限公司 2023-12-22 CN claimed
EP-1898952-A2 SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) Symrise GmbH & Co. KG (DE) 2008-03-19 EP claimed
US-20070258996-A1 Antimicrobial compositions THE STERILEX CORPORATION 2007-11-08 US claimed
US-20070054967-A1 SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) SYMRISE GMBH & CO. KG (DE) 2007-03-08 US claimed
WO-2006134160-A2 SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) SYMRISE GMBH & CO. KG (DE) 2006-12-21 WO claimed
WO-2005073154-A1 A METHOD OF EXTRACTING TOTAROL AND/OR A PRODUCT CONTAINING TOTAROL MENDE DOUGLAS ANTHONY (NZ) 2005-08-11 WO claimed
US-6881756-B2 Method for treating skin disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2005-04-19 US claimed
JP-2005507882-A 2005-03-24 JP claimed
EP-1435927-A2 METHOD FOR TREATING SKIN DISORDERS Johnson & Johnson Consumer Companies, Inc. (US) 2004-07-14 EP claimed
US-20030104016-A1 Method for treating skin disorders JOHNSON & JOHNSON CONSUMER INC. 2003-06-05 US claimed
WO-2003024436-A2 METHOD FOR TREATING SKIN DISORDERS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2003-03-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260131121-A1 MICRONEEDLE PATCH LIPA, CUTA, MMP1 CYP3A4 4752/4885MAPT 1414/4885USP2 3257/4885
US-20070054967-A1 SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) NR1H3, NR1H2, CBR3 CYP3A4 12/4885MAPT 3989/4885USP2 3439/4885
US-20030104016-A1 Method for treating skin disorders CUTA, MGLL, LIPA CYP3A4 1780/4885MAPT 850/4885USP2 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.